Abstract
INTRODUCTION
Hepatitis C virus (HCV) infection is a major health problem. The World Health Organization (WHO) estimates that at least 150-170 million people, approximately 3% of the world's population, are chronically infected. These patients are known to be at risk of liver related complications, i.e., cirrhosis and hepatocellular carcinoma (HCC), with an estimated liver-related mortality of 350000 people/year. The total risks of morbidity and mortality are underestimated, because they do not take into account extrahepatic consequences of HCV infection. Numerous extrahepatic manifestations have been reported, suggesting that HCV is more a systemic disease than just a liver disorder. In large prospective cohort studies, up to two-thirds of patients with HCV infection experienced extra-hepatic manifestations [1] . The majority of available data concern HCV-related autoimmune and/or lymphoproliferative disorders, from benign mixed cryoglobulinemia to frank lymphomas, which is consistent with HCV lymphotropism [2] . More recently, other HCV-associated disorders have been reported including cardiovascular, renal, central nervous system and metabolic diseases [3] . Among the latter, some studies assessed the risk of diabetes mellitus (DM) or insulin resistance (IR) while others evaluated the impact of DM/IR on the main liver-related HCV infection outcomes (i.e., liver fibrosis, cirrhosis, HCC). However, the results appear to be conflicting, with great heterogeneity between studies.
In the present study, based on a literature data review, we aimed to analyse: (1) the risk of glucose abnormalities (GA) in HCV-infected patients; and (2) the impact of GA on the main liver-related HCV outcomes, i.e., liver fibrosis, response to interferon alfabased treatment, and HCC.
MATERIALS AND METHODS
We conducted a PubMed search and selected all studies found with the key words "HCV" or "hepatitis C virus" and "diabetes" or "insulin resistance". We included only comparative studies written in English or in French, published from January 2000 to April 2015. We selected surveys that had evaluated the risk of Type 2 DM or IR in HCV-infected patients compared with healthy controls or with patients with hepatitis B virus (HBV) infection. The definition of DM was usually based on a fasting plasma glucose > 1.26 g/L, or a history of diabetes mellitus, or use of oral antidiabetic agents or insulin. The definition of IR was based on the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) according to the formula: HOMA-IR = fasting glucose (mmol/L) × fasting insulin (mIU/L)/22.5. We also included studies that assessed the association between the presence of glucose abnormalities (DM or IR) and the main HCV infection outcomes (i.e., liver fibrosis, cirrhosis, response to antiviral treatment, HCC). Conversely, studies that evaluated the impact of antiviral treatment on glucose abnormalities were included. We excluded studies with patients infected with the HBV or human immunodeficiency virus, and those for whom the entire manuscript was not available.
RESULTS

Is HCV infection associated with an increased prevalence of glucose abnormalities?
We included two types of studies: (1) those that assessed the HCV prevalence in diabetic patients compared with non-diabetics; and (2) studies that assessed the prevalence of DM and/or IR in HCVinfected patients compared with controls (healthy volunteers or HBV carriers) ( Table 1) .
Six studies evaluated HCV prevalence rates in diabetic patients compared with non-diabetic healthy volunteers. The number of participants ranged from 180 to 13000. Four out of the six studies showed a significant increased prevalence of HCV infection markers [HCV antibodies (n = 3), HCV RNA (n = 1)] in DM patients, with an odds ratio (OR) between 2.87 and 3.03 [4] [5] [6] [7] . Of note, only one study used multivariate Huang et al [6] Jadoon et al [7] Mehta et al [8] 2000 Shaheen et al [19] 2007 United States Huang et al [6] Huang et al [21] Park et al [20] 2008 South Korea Lonardo et al [24] Huang et al [25] 2009 Younossi et al [28] 2013 Pothineni et al [29] 2014 United States Retrospective Dai et al [30] Mehta et al [10] 2003 United States Case-control 
NS
Stepanova et al [11] 2012 United States Nationwide Ryu et al [31] 2001 South Korea Wang et al [32] 2007 Taiwan Huang et al [6] White et al [12] 2008 Rouabhia et al [34] logic regression analysis, while another adjusted the risk for age, gender, body mass index (BMI) and alanine aminotransferase (ALT) levels. One study showed an increased HCV antibody prevalence rate in DM patients with abnormal ALT levels. Thirty-two studies evaluated DM and/or IR prevalence rates in HCV patients compared with either healthy volunteers (n = 20) or HBV patients (n = 12). The size of cohorts ranged from 50 to 39506 subjects. All but four studies assessed DM/IR prevalence in HCV-RNA positive patients. In 10 out of 20 studies that compared HCV patients with healthy volunteers, multivariate or univariate analyses with adjustment for age, gender, BMI, socio-economic status and ethnicity were performed. Thirteen studies evaluated DM prevalence (n = 11) or occurrence (n = 2), while others (n = 9) assessed IR in HCV infected patients. Overall, 16 out of 20 studies found a significant association between the presence of glucose abnormalities (DM/IR) and HCV infection, including 7 out of 10 studies with multivariate or adjusted analyses (OR between 1.2 and 3.77). One study reported a higher risk of DM only in patients older than 40 years [8] . Four studies reported "negative" results. Three out these four studies showed a higher risk of DM only in specific populations (i.e., HCV patients with increased ALT levels [9] , HCV patients older than 55 years with a BMI > 25 kg/m 2 [10] , and a cohort studied between 1988 and 1994, but not in the more recent cohort) [11] .
When compared with HBV infected patients, 7 out of 11 studies found a significant association of HCV with DM. In one meta-analysis [12] , a positive HCV viremia was associated with an increased risk of DM compared with controls (adjusted OR = 1.68) and with HBV patients (adjusted OR = 1.80).
Are diabetes mellitus or insulin resistance associated with liver fibrosis severity in HCV infected patients?
Thirty studies investigated whether DM/IR was associated with liver fibrosis severity in HCV patients ( Table 2) . Studies were performed in Asia (Taiwan n = 3, Japan n = 3, other n = 1), Europe (n = 13), the United States and Australia (n = 5), Saudi Arabia (n = 1), Turkey (n = 1) and Egypt (n = 3). The mean size of the cohorts was 451 patients (min-max range 10 to 3068). The authors searched for an association between liver fibrosis severity and DM (n = 9), IR (n = 19) or impaired fasting plasma glucose (n = 2). All but two studies performed multivariate analyses. Twenty-six out of thirty studies reported a significant association of glucose abnormalities with liver fibrosis severity (OR from 1.28 to 13.72). Three of the four "negative" studies were done on small cohorts. There were some differences related to HCV genotypes, but no systematic relationship was found.
Do diabetes mellitus and insulin resistance have an impact on the virological response to HCV treatment?
Twenty-six studies and three meta-analyses investigated whether GA had an impact on the response to interferon alfa-based antiviral treatment (Table 3 ). The studies originated from Europe (n = 11), Asia (n = 4), Egypt (n = 4), the United States (n = 5), Australia (n = 1) and Saudi Arabia (n = 1). They included a mean of 503 patients (50 to 5944). Nineteen out of twenty-eight studies showed a significant negative effect of GA in response to interferon alfa-based therapy [i.e., lower sustained viral response (SVR) rates], including 15 multivariate analyses and 3 meta-analyses. Of note, studies that did not find an impact of GA on SVR rates had some limitations, including small size of cohorts (60-600 patients), only G1 or G4 patients (3 out of 10 studies), and only Italian patients (4 out of 10). Two of them evaluated patients treated with peginterferon/ribavirin and telaprevir. The three meta-analyses found a significant association between IR and the absence of SVR, regardless of the genotype (OR for G1 = 2.2, G2 = 3, G3 = 4.45 and G4 = 6.7, respectively).
Petta et al [56] [60] 
What is the impact of interferon alfa-based treatment on glucose abnormalities?
Twenty studies assessed the impact of interferonbased antiviral treatment on DM/IR, either as an improvement of GA after treatment or as the occurrence of GA after antiviral treatment (Table 4) . Improvement of GA after antiviral treatment was analysed in fifteen surveys that included 13 to 1038 HCV treated patients. Most of these studies performed univariate analyses. A significant decreased prevalence of GA was noted in 12 out of 15 studies. Eleven of these 12 studies reported a significant change of IR 
Genotypes Statistics
Konrad et al [42] 2000 Germany 10 Non DM FPG Multivariate Yes All p = 0.01 Sud et al [61] [63] 2005
United Kingdom [70] 2009 [60] 2009
Italy 726 -DM Multivariate Yes All p < 0.05 Hung et al [14] 2011
Taiwan 1470 -DM Univariate Yes All p < 0.001 Patel et al [72] [76] only in patients who achieved a SVR. One survey found a significant change of IR after antiviral treatment only in genotype 1 patients [13] . Five studies evaluated the risk of GA occurrence according to antiviral treatment response. They included 202 to 2842 HCV treated patients, and all performed multivariate analyses. Four out of five studies showed a significant association between GA occurrence and the absence of SVR.
Do glucose abnormalities increase the risk of HCC in HCV infected patients?
Sixteen studies assessed the association between HCC and DM/IR in HCV infected patients (Table 5 ). These studies included from 120 to 5186 HCV patients, both treated and non-treated. Most of them (10/16) [94] 2011
France 2732 G1-6 IR Meta-analysis Yes All -Eslam et al [95] 2011 [76] [103] included Asian patients, and all but one performed multivariate analyses. Five studies looked for the presence of DM/IR in HCV infected patients with HCC compared with HCV patients without HCC. Four out of five studies found a significant association between DM/IR and HCC (as compared with non-HCC) (OR from 2.0 to 11.6).
Nine out of eleven other studies found a significant association between the presence of DM/IR and the development of HCC in the follow-up of HCV infected patients (HR from 1.10 to 6.9). One study found a higher risk of HCC in diabetic patients only with SVR and without cirrhosis [14] , while 2 others reported an increased risk of HCC only in diabetic patients with advanced fibrosis [15, 16] .
DISCUSSION
Many studies have evaluated the association between HCV chronic infection, insulin-resistance and diabetes mellitus. The abnormalities of carbohydrate metabolism, including hyperinsulinemia and IR, known to be per se related to chronic hepatic diseases, were the rationale for speculation on this relationship. Insulinresistance is an often undetected condition, commonly coexisting with obesity and metabolic syndrome, and possibly progressing to type 2 diabetes. HCV-related type 2 diabetes mellitus may arise from a complex interaction between IR, steatosis and inflammatory processes. Epidemiologic studies supporting the association between type 2 diabetes and HCV infection were
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Glucose metabolism parameter
Statistical method
Significant association or difference Genotypes Statistics
Improvement of glucose abnormalities after HCV treatment Konrad et al [42] 2000 United States 13 FPG and FI Univariate Yes All p < 0.05 and p < 0.01 Romero-Gomez et al [86] 2005 Spain 50 HOMA-IR Univariate Yes All In SVR; p < 0.05 Kawaguchi et al [106] 2007 Japan 89 HOMA-IR Univariate Yes All In SVR; p < 0.01 Chehadeh et al [107] 2009
Kuwait 181 G4 FPG Univariate Yes G4 In SVR; p < 0.001 Kim et al [108] [75] 2011 United States 341 G1 HOMA-IR Univariate Yes G1 In SVR; p < 0.001 Khattab et al [76] 2012 Egypt 107 G4, non cirrhotic HOMA-IR Univariate Yes G4 In SVR ; p = 0.001
Thompson et al [13] 2012 United States 1038 HOMA-IR Multivariate 1 Yes All In G1 SVR; p = 0.007 Serfaty et al [103] 2012
France 161 G1, non cirrhotic HOMA-IR Univariate Yes G1 In SVR ; p < 0.05
Ziada et al [77] 2012 Egypt 140 Non DM, non cirrhotic
Chan et al [109] 2013 Australia 86 Non DM HOMA-IR Univariate Yes All In SVR; p = 0.04 Jung et al [105] 2014 South Korea 60 HOMA-IR Univariate Yes All In SVR; p = 0.036 Mello et al [110] 2006 Brazil 30 G1, G3 HOMA-IR Univariate No All NS Kawaguchi et al [111] [114] first published in the early 1990s. More recently, larger epidemiologic studies gave more in-depth analyses of the relationship between HCV chronic infection and glucose abnormalities and were included in the present analysis.
HCV infection is associated with increased rates of glucose abnormalities, including diabetes mellitus and insulin resistance
In the present analysis, most studies found a significant association between HCV infection (whether active HCV RNA positive, or not i.e., HCV Ab positive) and diabetes mellitus or insulin resistance. This tight association was confirmed in both directions by the increased rates of HCV infection markers in DM/IR patients and the high rates of glucose abnormalities in HCV infected patients. The consistency of this association was supported by the confirmation of such results compared with different control groups, such as healthy volunteers or HBV carriers [6, 8, 12, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . The variability of HOMA-IR cut-offs used (between 1.8 and 2.5 generally) may explain the heterogeneous results reported in the literature. Confounding factors might have also led to significant bias. Indeed, some studies comparing HCV patients with healthy volunteers did not perform multivariate analysis or adjust for confounding factors. However, seven out of ten multivariate analyses found a significant increased risk of DM/IR in HCV patients (OR = 1.2-3.7), after adjusting for confounding variables such as age, gender, BMI, ethnicity and education level.
How are we able to explain the increased risk of DM in HCV infected patients? Some authors have suggested that diabetic patients might have been infected by HCV due to injections or nosocomial transmission. The association of HCV infection with IR and the widespread use of universal precautions nowadays in hospitals to avoid virus transmission probably dis-
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Diabetes mellitus/insulin resistance in HCV-related HCC K-Kutala et al [15] 2014 Hung et al [115] 2010 [115] 2010 [116] 2012 [117] 2008 Veldt et al [16] 2008 [14] 2010 [122] 2015 [123] 2006 Taiwan 2141 -DM and HCC Multivariate No NS Chen et al [124] 2013 Taiwan [6, 12, 17, [31] [32] [33] [34] . The ability of HCV, particularly genotype 3 viruses, to induce liver steatosis on its own, which might in turn increase the risk of DM/IR, has also been suggested in previous studies [35, 36] . Other underlying mechanisms may involve HCV per se. Experimental data suggest the role of inflammation. Increased HOMA-IR has been correlated with soluble Tumor Necrosis Factor Receptor1 (sTNFR1) and sTNFR2 levels [37] . Increased abnormal HOMA-IR was not associated with elevated serum levels of TNFα, IL6 and adiponectin in another study [38] . Other studies have also suggested an impairment of glucose uptake in HCV-infected patients. Glucose uptake and the surface expression of Glucose Transporters (GLUT1 and 2) were suppressed in cells infected by HCV compared with controls [39] . Interferon alfa restored glucose uptake, GLUT2 surface expression, mRNA expression and GLUT2 promoter activities. HCV has also been shown to impair glucose uptake and to promote IR by increasing suppressor of cytokine signalling 3 (SOC3), which inhibits insulin phosphorylation of AKT and phosphoinositide 3-kinase (PI3K) [40] . HCV may be involved in the regulation of phosphorylation of insulin receptor substrate 1 (ISR-1), implicated in the insulin pathway [41] . In HCV core transgenic mice, the viral protein was able to induce increasing TNFα levels in the liver, which in turn promoted the induction of IR. The high levels of TNFα inhibited the ISR-1, causing IR and its possible progression to diabetes. A decreased expression of ISR-1 and ISR-2 mediated by ubiquitination was observed and was inversely proportional to the liver fibrosis stage.
Interferon alfa use might lead to glucose metabolism impairment and is a potential bias. However, increased DM/IR rates have been also reported in HCV patients not taking interferon alfa [20, [22] [23] [24] [25] 34] . Many studies found a decreased rate of glucose abnormalities in HCV patients who showed a SVR after interferon alfabased therapy, and even in non virological responders in one study [42] . This strongly suggests a direct/indirect role of HCV on glucose metabolism impairment. As eradication of HCV seems to be effective in decreasing the occurrence rate of DM/IR, it will very be interesting to analyse the impact of new direct antiviral agents (DAAs) for preventing DM/IR and eventually cardiovascular disorders. Indeed, in a recent study, IFN-free antiviral regimen resulted in rapid changes in serum lipid profiles and intrahepatic expression of lipid-related genes in G1 patients [43] .
Presence of glucose abnormalities in HCV infected patients, including diabetes mellitus and insulin resistance, is associated with negative liver-related outcomes
Severe liver fibrosis, the absence of SVR after interferon alfa-based treatment, and the development of HCC are the main negative outcomes of chronic HCV infection. Interestingly, the presence of DM or IR in HCV patients showed a pejorative impact on each of these end points. Most studies found an independent association of glucose abnormalities with advanced liver fibrosis, absence of SVR after antiviral treatment and HCC occurrence. Only few studies did not confirm such associations. This might be explained by the small size cohort of such studies, the heterogeneity of criteria for DM or HOMA-IR and the very high prevalence of other metabolic risk factors (such as elevated BMI) which may underestimates the impact of DM/IR. Our data is consistent with recent studies that demonstrated that DM increases cumulative incidence of decompensated cirrhosis [44] . In another recent survey, diabetes was independently associated with transplantation-free survival, development of ascites, renal dysfunction, bacterial infections, and HCC during the follow-up [45] . Experimental data suggest that increased insulin levels after hyperglycaemia leads to interferon signalling impairment. Insulin may inhibit the ability of interferon alfa to block HCV replication due to the activation of PI3K by insulin, thus leading to inhibition of STAT-1, which is involved in the interferon alfa pathway [40] . The impact of glucose abnormalities on virological response needs to be further evaluated with new DAA, interferon-free combinations. To date, there is very few data on the impact of GA on virological response to new DAA. Preliminary results suggest that the presence of diabetes does not appear to be predictive of treatment failure in G1 patients [46, 47] . Further studies are needed to confirm these data and to evaluate the impact of DM on SVR in patients without poor prognostic factors.
Should glucose abnormalities be corrected to increase SVR rates?
A prospective study, including 155 HCV genotype 1 patients with IR, showed no difference in SVR rates after peginterferon alfa and ribavirin were given, regardless of whether or not patients had received pioglitazone, an antidiabetic drug [48] . Of note, most glycemic control indexes improved significantly in the pioglitazone group except for HbA1c. Another study found higher SVR rates in G4 patients treated with pioglitazone [49] . Pioglitazone may alter NK cell functions and thus impair clearance of infected hepatocytes [48] . A retrospective cohort from Taiwan (19349 diabetic patients, 1.7% HCV positive) showed that patients taking metformin and thiazolidinediones had the lowest risk of HCC (HR 0.49 and 0.56, respectively) after adjusting for age, gender and comorbidities [50] . Consistently, in a prospective cohort of 100 HCV patients with ongoing cirrhosis, metformin treatment was independently associated with a decrease of HCC occurrence and liver-related death or transplantation [51] . In a two-year prospective follow-up of 85 patients with HCV-related HCC, HCC recurrence-free survival was increased in diabetics taking pioglitazone vs non-treated diabetics (44.2% vs 36.5%, respectively, p = 0.37) [52] . A significant decrease in HCC recurrence was observed in the pioglitazone group for patients with a BMI > 24.
We acknowledge some limitations of this study. Although we tried to include all published studies, we may have missed others in non-English literature or data only presented at meetings. Some studies were done with a limited number of patients. For some studies included in the present analysis, it is possible that there are some remaining bias and residual confounding factors. Despite multivariate analyses, the association between glucose abnormalities improvement and improved outcome may have been influenced by unmeasured confounding factors. Such final confirmation should arise from controlled clinical trials with long-term follow-up.
In conclusion, HCV chronic infection is associated with an increased risk of DM or IR, by a likely direct effect on glucose metabolism. In such patients, DM and IR are associated with a pejorative liver-related prognosis, as shown by increased rates of severe liver fibrosis, HCC occurrence, and decreased SVR rates after interferon-based therapy. This tight relationship between DM/IR and HCV infection needs to be further analysed with new DAAs, interferon-free combinations, with special attention to improvement in glucose abnormalities and long-term follow-up.
COMMENTS
Background
During hepatitis C virus (HCV) infection, extra-hepatic disorders are very frequent and polymorphous. Studies that have evaluated the link between glucose metabolism impairment and HCV reported heterogeneous data.
Research frontiers
Further studies are needed to evaluate the impact of glucose abnormalities in patients treated with interferon-free antiviral therapies. The effects of correction of glucose abnormalities in reducing liver event rates also need to be further studied.
Innovations and breakthroughs
This systematic review allows clarifying the close relationship between glucose abnormalities, HCV infection and poor liver outcomes. HCV infection is associated with increased rates of glucose abnormalities, including diabetes mellitus and insulin resistance. The presence of glucose abnormalities in HCV infected patients, including diabetes mellitus and insulin resistance, is associated with negative liver-related outcomes (i.e., severe liver fibrosis, decreased response to antivirals, and increased occurrence of hepatocellular carcinoma).
Applications
These data strongly encourage clinicians to systematically screen HCV-infected patients for the presence of glucose abnormalities. Considering the impact of glucose abnormalities on liver-related outcomes in HCV infected patients, antiviral treatment should also be considered in HCV-infected patients with metabolic syndrome.
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This review talks about the relationship between HCV infection and glucose abnormalities. There are already lots of articles about the topic. This review summarizes those articles published from January 2000 to April 2015 in PubMed and gives us a conclusion about the topic.
